MUMBAI (TIP): US-based Merck and Sun Pharma have entered into an exclusive worldwide licensing agreement for Merck’s dermatology molecule, tildrakizumab, which is under phase 3 registration trials. Tildrakizumab is being developed for the treatment of chronic plaque psoriasis, a skin ailment. Under the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab from Merck for an upfront payment of $80 million. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the product.